Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 14, 2014 - Issue 1
Submit an article Journal homepage
262
Views
1
CrossRef citations to date
0
Altmetric
Drug Profile

Cost–effectiveness of abatacept for moderate-to-severe rheumatoid arthritis

Nicole W TsaoCollaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, Canada V6T 1Z3
,
Kam ShojaniaDivision of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, Canada
&
Carlo A MarraCollaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, Canada V6T 1Z3Correspondence[email protected]
Pages 9-18 | Published online: 10 Dec 2013

References

  • Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res. Ther. 11(3), 229 (2009).
  • Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 4(3), 130–136 (2005).
  • Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 46(3), 625–631 (2002).
  • Canadian Agency for Drugs and Technologies in Health. Clinical and economic overview: Biological response modifier agents for adults with rheumatoid arthritis. CADTH, Ottawa, Canada 2010.
  • Bykerk VP, Akhavan P, Hazlewood GS et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J. Rheumatol. 39(8), 1559–1582 (2011).
  • Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. Clin. Rheumatol. 30(Suppl. 1), S3–S8 (2011).
  • Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 358(9285), 903–911 (2001).
  • Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(2 Suppl. 1), 1–12 (2004).
  • Rupp I, Boshuizen HC, Dinant HJ, Jacobi CE, Van den Bos GAM. Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand. J. Rheumatol. 35(3), 175–181 (2006).
  • Lundkvist J, Kastäng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur. J. Health Econ. 8(Suppl. 2), S49–S60 (2008).
  • Badley, E, Rasooly, I, Webster, G. Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability, and health care utilization: findings from the 1990 Ontario Health Survey. J. Rheumatol. 21(3), 505–514 (1994).
  • Turesson C, Jacobsson LTH, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc. Health Risk Manag. 4(3), 605–14 (2008).
  • Gabriel SE, Crowson CS, Kremers HM et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 48(1), 54–58 (2003).
  • Young A, Koduri G, Batley M et al. Mortality in rheumatoid arthritis: Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46(2), 350–357 (2007).
  • Sacks JJ, Helmick CG, Langmaid G. Deaths from arthritis and other rheumatic conditions, United States, 1979–1998. J. Rheumatol. 31(9), 1823–1828 (2004).
  • Gonzalez A, Maradit Kremers H, Crowson CS et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 56(11), 3583–3587 (2007).
  • Farragher TM, Goodson NJ, Naseem H et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum. 58(2), 359–369 (2008).
  • Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 71(9), 1524–1529 (2012).
  • Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 373(9664), 659–672 (2009).
  • Newton JL, Harney SMJ, Wordsworth BP, Brown MA. A review of the MHC genetics of rheumatoid arthritis. Genes Immun. 5(3), 151–157 (2004).
  • Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr. Opin. Rheumatol. 21(3), 279–283 (2009).
  • Edwards CJ, Cooper C. Early environmental factors and rheumatoid arthritis. Clin. Exp. Immunol. 143(1), 1–5 (2006).
  • Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. Scand. J. Rheumatol. 35(3), 169–174 (2006).
  • Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 118(11), 3537–3545 (2008).
  • Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 20(5), 865–878 (2006).
  • Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40(2), 205–211 (2001).
  • Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31(3), 315–324 (1988).
  • Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62(9), 2569–2581 (2010).
  • Anderson J, Caplan L, Yazdany J et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res. (Hoboken) 64(5), 640–647 (2012).
  • American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 57(2), 193–202 (2007).
  • Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual. Life Outcomes 1, 20 (2003).
  • Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis. Care Res. (Hoboken) 64(5), 625–639 (2012).
  • Tarride J-E, Haq M, Nakhai-Pour HR et al. The excess burden of rheumatoid arthritis in Ontario, Canada. Clin. Exp. Rheumatol. 31(1), 18–24 (2013).
  • Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39(1), 28–33 (2000).
  • Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 23(3), 243–257 (2005).
  • Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr. Med. Res. Opin. 26(1), 77–90 (2010).
  • Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964–975 (2010).
  • Tayar JH, Suarez-Almazor ME. New understanding and approaches to treatment in rheumatoid arthritis. Br. Med. Bull. 94(1), 201–214 (2010).
  • Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J. Manag. Care Phar. 17(9), 14 (2011).
  • Bansback N, Marra CA. Now that we know what's BeSt, what is good value for the money? Arthritis Rheum. 61(3), 289–290 (2009).
  • Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 7(1), e30275 (2012).
  • Emery P. The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin. Investig. Drugs 12(4), 673–681 (2003).
  • Kotzin BL, Kappler J. Targeting the T cell receptor in rheumatoid arthritis. Arthritis Rheum. 41(11), 1906–1910 (1998).
  • Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 37(2), 234–245 (2010).
  • Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 54(9), 2807–2816 (2006).
  • Weinblatt M, Schiff M, Goldman A et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 66(2), 228–234 (2007).
  • Genovese MC, Becker J-C, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11), 1114–1123 (2005).
  • Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12), 865–876 (2006).
  • Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 67(8), 1096–1103 (2008).
  • Corbo M, Valencia X, Raymond R. Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity. Ann. Rheum. Dis. 68(Suppl. 3), S574 (2009).
  • Genovese MC, Covarrubias A, Leon G et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 63(10), 2854–2864 (2011).
  • Genovese M, Cobos A, Leon G. Subcutaneous (sc.) abatacept (ABA) versus intravenous (IV) ABA in patients (pts) with rheumatoid arthritis: long-term data from the ACQUIRE (Abatacept Comparison of sub[QU]cutaneous versus intravenous in Inadequate Responders to methotrexatE) trial. Arthritis Rheum. 63, S150 (2011).
  • Alten R, Kaine J, Keystone E. Safety of subcutaneous abatacept in patients with rheumatoid arthritis (RA): integrated analysis of five clinical trials up to 4.5 years. Ann Rheum Dis. 70(Suppl. 3), 617 (2011).
  • Alten R, Kaine J, Keystone E. Safety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposure. Arthritis Rheum. 63(Suppl. 10), 403 (2011).
  • Nash P, Nayiager S, Genovese MC et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis. Care Res. (Hoboken) 65(5), 718–728 (2013).
  • Keystone EC, Kremer JM, Russell A et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann. Rheum. Dis. 71(6), 857–861 (2012).
  • Weinblatt ME, Schiff M, Valente R et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 65(1), 28–38 (2013).
  • Drummond M, Schulpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programmes (3rd Edition). Oxford University Press, NY, USA 2005.
  • Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J. Health Serv. Res. Policy 9(2), 110–118 (2004).
  • Tsao NW, Bansback NJ, Shojania K, Marra CA. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 26(5), 659–676 (2012).
  • Saraux A, Gossec L, Goupille P et al. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology (Oxford) 49(4), 733–740 (2010).
  • Russell A, Beresniak A, Bessette L et al. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin. Rheumatol. 28(4), 403–412 (2009).
  • Beresniak A, Ariza-Ariza R, Garcia-Llorente JF, Ramirez-Arellano A, Dupont D. Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain. Int. J. Inflam. 2011, 1–9 (2011).
  • Cimmino MA, Leardini G, Salaffi F et al. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Clin. Exp. Rheumatol. 29(4), 633–641 (2011).
  • Puolakka K, Blåfield H, Kauppi M et al. Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland. Open. Rheumatol. J. 6, 38–43 (2012).
  • Beresniak A, Baerwald C, Zeidler H et al. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Clin. Exp. Rheumatol. 31(3), 400–408 (2013).
  • Vera-Llonch M, Massarotti E, Wolfe F et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J. Rheumatol. 35(9), 1745–1753 (2008).
  • Hallinen TA, Soini EJO, Eklund K, Puolakka K. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 49(4), 767–777 (2010).
  • Yuan Y, Trivedi D, Maclean R, Rosenblatt L. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. J. Med. Econom. 13(1), 33–41 (2010).
  • Vera-Llonch M, Massarotti E, Wolfe F et al. Cost–effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology 47(4), 535–541 (2008).
  • Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol. Assess. 15(14) (2011).
  • Marra CA, Marion SA, Guh DP et al. Not all “quality-adjusted life years” are equal. J. Clin. Epidemiol. 60(6), 616–624 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.